A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Dec 20, 2016

Astellas Announces FDA Fast Track Designation for ASP0892, DNA Vaccine for Mitigation of Severe Hypersensitivity Reactions due to Peanut Allergy

Tokyo, December 20, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) and Immunomic Therapeutics, Inc. (Founder & CEO: William Hearl, Ph.D., “Immunomic...

Read more about Astellas Announces FDA Fast Track Designation for ASP0892, DNA Vaccine for Mitigation of Severe Hypersensitivity Reactions due to Peanut Allergy
Dec 19, 2016

Marketing Approval of LINZESS®, Treatment for Irritable Bowel Syndrome with Constipation in Japan - Provides a new therapeutic option for adult patients suffering from irritable bowel syndrome with constipation (IBS-C) -

Tokyo, December 19, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it obtained a marketing approval for a guanylate cyclase-C (GC-C)...

Read more about Marketing Approval of LINZESS®, Treatment for Irritable Bowel Syndrome with Constipation in Japan - Provides a new therapeutic option for adult patients suffering from irritable bowel syndrome with constipation (IBS-C) -
Dec 15, 2016

Sysmex, Astellas and Daiichi Sankyo Sign Memorandum of Understanding on the Creation of a Method for Analyzing Circulating Tumor Cells

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu), Astellas Pharma Inc. (HQ: Tokyo, Japan; President and CEO: Yoshihiko Hatanaka) and Daiichi Sankyo Co., Ltd. (HQ: Tokyo,...

Read more about Sysmex, Astellas and Daiichi Sankyo Sign Memorandum of Understanding on the Creation of a Method for Analyzing Circulating Tumor Cells
Dec 14, 2016

Pfizer and Astellas Announce Top-Line Results from Phase 4 PLATO Trial of XTANDI® (enzalutamide) Capsules in Patients with Metastatic CastrationResistant Prostate Cancer

Read more about Pfizer and Astellas Announce Top-Line Results from Phase 4 PLATO Trial of XTANDI® (enzalutamide) Capsules in Patients with Metastatic CastrationResistant Prostate Cancer
Dec 12, 2016

Astellas Announces Transfer of Qutenza to Grünenthal

TOKYO and CHERTSEY – 12 December, 2016: Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”), today announced that Astellas Pharma Europe Ltd. (“Astellas Pharma...

Read more about Astellas Announces Transfer of Qutenza to Grünenthal

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts